EC Number   |
Application  |
Reference |
|---|
   3.4.17.23 | medicine |
ACE-2 protects against lung fibrogenesis by limiting the local accumulation of the profibrotic peptide angiotensin II |
677486 |
| 3.4.17.23 | medicine |
ACE2 activators are a reliable approach which could lead to the development of a novel class of antihypertensive and cardioprotective drugs |
693702 |
| 3.4.17.23 | medicine |
ACE2 is a functional receptor for the causative agent of severe acute repiratory syndrome, the SARS coronavirus, ACE2 also plays a role in the development of liver fibrosis and subsequent cirrhosis |
678102 |
| 3.4.17.23 | medicine |
ACE2 is a key factor for protection from ARDS/acute lung injury and it functions as a critical SARS receptor in vivo, recombinant ACE2 protein might not only be a treatment to block spreading of SARS but also to protect SARS patients from developing lung failure |
679135 |
| 3.4.17.23 | medicine |
ACE2 may be a target for therapeutic interventions that aim to reduce albuminuria and glomerular injury |
680388 |
| 3.4.17.23 | medicine |
ACE2 offers a new target for the treatment of hypertension and other cardiovascular diseases |
691838 |
| 3.4.17.23 | medicine |
ACE2 protects against acute lung injury in several animal models of acute respiratory distress syndrome. Increasing ACE2 activity might be a novel approach for the treatment of acute lung failure in several diseases |
668354 |
| 3.4.17.23 | medicine |
ACE2 protects murine lungs from acute respiratory distress syndrome |
679703 |
| 3.4.17.23 | medicine |
ACE2-overexpressing A549 cell-derived microparticles are a potential therapeutic agent against SARS-CoV-2 infection. Intranasally administered microparticles dexterously navigate the anatomical and biological features of the lungs to enter the alveoli and are taken up by alveolar macrophages. Then, ACE2-overexpressing A549 cell-derived microparticles increase the endosomal pH but decrease the lysosomal pH in alveolar macrophages, thus escorting bound SARS-CoV-2 from phago-endosomes to lysosomes for degradation. In addition, ACE2-overexpressing A549 cell-derived microparticles also inhibit the proinflammatory phenotype of alveolar macrophages, leading to increased treatment efficacy in a SARS-CoV-2-infected mouse model without side effects |
764444 |
| 3.4.17.23 | medicine |
administration of ACE2 activators may be a valid strategy for antihypertensive therapy |
692586 |
